All posts by imreal

Technology: Computer

RIT professors co-author study on detecting fake Amazon reviews

Leave a comment

[ad_1]

graphic featuring an overlay of a 4.5 star customer review on a person typing on a laptop.

New research co-authored with others by two Saunders College of Business faculty researchers provides one method for searching out five-star fakes. (Shutterstock)


ROCHESTER, N.Y. (PRWEB)

It doesn’t have to be the holidays for Amazon to receive a lot of attention from product buyers, but business on the nation’s largest online retailer is especially brisk this time of year.

While the company says it has over 12,000 employees who look for fraud on its site, the growing glut of fake reviews leaves one wondering whether that device or accessory you’re considering is truly so highly rated.

New research co-authored with others by Ali Tosyali and Gijs Overgoor, assistant professors in the Department of MIS, Marketing, and Analytics at RIT’s Saunders College of Business, provides one method for searching out five-star fakes.

In the study, titled, “Detecting Fake Review Buyers Using Network Structure: Direct Evidence from Amazon,” Tosyali and Overgoor:


  • Employed network science and machine learning to develop a highly accurate method for detecting fake reviews.

  • Revealed that products that purchase fake reviews share a common set of reviewers, predominantly among Facebook groups, which are highly clustered in a product-reviewer network.

  • Claim their research method is highly accurate and, unlike approaches relying on reviews’ text, their approach is more resistant to manipulation by sellers.

The research, featured in The Wall Street Journal earlier this year, offers a promising means of helping consumers avoid being duped by these fraudulent and misleading reviews. The paper has been published on pnas.org.

The two RIT professors became involved in the research after Tosyali’s personal experience purchasing a vitamin on Amazon. “The product I purchased had many reviews—approximately 5,000—with an average rating of 4.9,” Tosyali recalled. “After using it, I observed some side effects and returned the product.”

Upon returning the product, Tosyali looked at the reviews more closely and saw many negative comments, which referenced the side effects he experienced.

“However, because of the large number of five-star reviews, the product looked pretty satisfactory,” Tosyali observed. “At that point, I wondered if there was a way to detect fake reviews that mislead customers.”

During a follow-up conversation with Overgoor, Tosyali mentioned his experience and the two Saunders College faculty decided to look into the issue more closely.

Overgoor later discovered that some UCLA colleagues had initiated a paper analyzing the market of fake reviews using a dataset of Amazon reviews, and the researchers agreed to collaborate.

The dataset used took about nine months to collect, with the help of UCLA undergrads who infiltrated Facebook groups where fake reviews are solicited. After identifying sellers and products for which faux reviews were gathered, all reviews were then combined together. The research took about a year, employing techniques from network science, machine learning, and text and image analysis.

Based on their research, Tosyali and Overgoor offer the following tips for consumers to spot fake Amazon reviews.

  • Compared to products not buying fake reviews, products that purchase fake reviews are highly connected and clustered in the network, implying that products buying fake reviews tend to have more reviewers in common than other products.

  • While regular products receive their reviews from a dispersed set of millions of Amazon customers, products purchasing fake reviews must rely on the relatively small number of reviewers participating in the “fake review marketplace.”

  • Features derived from the product-reviewer network are especially useful for detecting fake reviews because—in addition to being more predictive than text or metadata features—they are more difficult or costly to manipulate by sellers than text or review timing.

According to the RIT researchers, e-commerce platforms can use the research “as a flagging mechanism,” and “the research increases customers’ awareness of these harmful initiatives.”

“They could be more vigilant about five-star reviews and be aware that five-star reviews could be paid,” Tosyali said.

The team is working on additional research on this topic, Overgoor added.

Share article on social media or email:

[ad_2]

Health

Youth receive nutritional support at Don Bosco Kansebula thanks to donor funding from Salesian Missions

Leave a comment

[ad_1]

News Image


NEW ROCHELLE, N.Y. (PRWEB)

DR CONGO: Youth receive nutritional support at Don Bosco Kansebula thanks to donor funding from Salesian Missions.

Don Bosco Kansebula also has a 44-hectare farm that supplies food.

More than 360 youth received nutritional support at Don Bosco Kansebula, located in Lubumbashi, Democratic Republic of the Congo*, thanks to donor funding from Salesian Missions, the U.S. development arm of the Salesians of Don Bosco.

Youth benefiting from this food were ages 6-22. Many are are in secondary school and college as well as 82 young Salesians studying at Don Bosco Kansebula. Single mothers from the villages also received this donation. The goal was to provide ongoing balanced nutrition for young Salesians and other vulnerable youth.

Don Bosco Kansebula also has a 44-hectare farm that supplies food for the Salesian formation house and to the village nearby. Since its beginning, Don Bosco Kansebula has provided young Salesians with philosophy education and has given them shelter and nutritional support while at the school. Villagers living near Don Bosco Kansebula have used the farm to cultivate food for themselves and the community.

One of the beneficiaries was Kyundundu Mbilizi Fabrice, who is 25 and in high school, Fabrice said, “I studied agriculture in the eastern part of the Democratic Republic of the Congo at Uvira. Now, I am at Kansebula as Salesian of Don Bosco in post-novitiate. At Kansebula, we have a garden and we produce vegetables and keep some domestical animals. Villages and confreres have benefited from what is produced in the garden and in the farm as well. I am really happy for what our benefactors are doing for us in order to fight hunger and I encourage them to continue in that direction.”

Salesian missionaries have been working in the Democratic Republic of the Congo for more than 100 years ensuring that the most vulnerable children are not forgotten. Salesian primary and secondary schools and programs lay the foundation for early learning while Salesian trade, vocational, and agricultural programs offer many youth the opportunity for a stable and productive future.

Despite its vast material wealth, the Democratic Republic of the Congo has long been a very poor nation. Half of the country’s population lives below the poverty line, living on less than $1 a day, especially those in rural communities. Because of ongoing strife and violence within the country, more than 8.5 million people are in urgent need of humanitarian assistance. More than 4.1 million Congolese are now displaced, with 620,000 seeking refuge in neighboring countries. More than 7.5 million people do not have enough food to eat.

*Any goods, services, or funds provided by Salesian Missions to programs located in this country were administered in compliance with applicable laws and regulations, including sanctions administered by the U.S. Department of Treasury’s Office of Foreign Asset Control.

###

About Salesian Missions USA

Salesian Missions is headquartered in New Rochelle, NY, and is part of the Don Bosco Network—a worldwide federation of Salesian NGOs. The mission of the U.S.-based nonprofit Catholic organization is to raise funds for international programs that serve youth and families in poor communities around the globe. The Salesian missionaries are made up of priests, brothers and sisters, as well as laypeople—all dedicated to caring for poor children throughout the world in more than 130 countries and helping young people become self-sufficient by learning a trade that will help them gain employment. To date, more than 3 million youth have received services funded by Salesian Missions. These services and programs are provided to children regardless of race or religion. For more information, go to SalesianMissions.org.

Contact:

Hannah Gregory

media@salesianmissions.org

914-960-4642 (text messages OK)

Twitter: @MissionNewswire

Newswire: MissionNewswire.org

Press room: SalesianMissions.org/press

Share article on social media or email:



[ad_2]

Health

Daniel Crowder Brings Trucking and Transportation Industry Expertise to Resonea

Leave a comment

[ad_1]

Dan Crowder brings 24 years of trucking and transportation experience to Resonea

Obstructive sleep apnea is more prevalent in transportation than any other industry.


SCOTTSDALE, Ariz. (PRWEB)

Resonea, Inc. a medtech company focused on sleep health in the trucking industry, today announced that Dan Crowder has joined the company as Regional Vice President of Sales.

“Dan Crowder is an industry expert with 24 years of experience in the trucking and transportation industry,” said Dr. Karen Underwood, chief medical officer at Resonea. “His proven success in market development, account management, client relations and customer service, along with his exceptional leadership, teamwork, communications and organizational skills, will be a key part of our ongoing growth.”

Throughout his career, Crowder has worked for industry leading providers developing effective sales strategies and establishing partnerships with customers. Most recently, he was the president of Equipment Sales Group, a manufacturers representation firm focused on customer direct sales with fleets, leasing companies, OEMs and distributors.

Previously, Crowder served at E-SMART Control, the developer of safety and speed management technology, Transtex Composite, the manufacturer of aerodynamic products, and at Johnson Refrigerated Truck Bodies and Mickey Truck Bodies. Earlier in his career, he held management roles at Idealease, Xtra Lease, Ryder Integrated Logistics and WH Smith, Inc. Crowder is an honored military veteran, having attained the rank of Captain in the United States Army Infantry, 101st Airborne Division.

“Obstructive sleep apnea is more prevalent in transportation than any other industry,” Crowder said. “With driver health and wellness an essential issue to address, the DROWZLE Sleep Health Program is an effective, unobtrusive, simple and economical solution for drivers and fleets. I am excited to continue my career bringing Resonea products and services to trucking where they have great potential to positively impact a driver’s quality of life.”

About Resonea, Inc.

Arizona based Resonea, Inc. is a medtech company focused on advancing sleep health technology to improve the performance, safety and quality of life of people in safety-critical positions such as professional truck drivers. Resonea’s patented DROWZLE® family of products and partner solutions provide companies with an end-to-end program for Obstructive Sleep Apnea (OSA), including the first FDA-cleared digital OSA screening tool accessed from a smartphone. Companies looking to reduce the effects of fatigue in their workforce and document their investment can offer Resonea’s comprehensive programs of sleep education, screening/testing/treatment, compliance monitoring and reporting to their employees. For more information see http://www.Resonea.com.

Share article on social media or email:

[ad_2]

Health

Engaging with the FDA Webinar on December 1, 2022

Leave a comment

[ad_1]


FALLS CHURCH, Va. (PRWEB)

Steve Silverman, president of The Silverman Group, and former director of the Center for Devices and Radiological Health’s (CDRH) Office of Compliance and assistant director of the Center for Drug Evaluation and Research’s (CDER) Office of Compliance, will share how to engage effectively with the FDA.

He will explain what effective FDA engagement is, what it will and will not provide, the best engagement practices, and the right level of engagement.

Webinar Takeaways:


  • What effective FDA regulatory engagement means as well as misperceptions to be aware of

  • The four essential principles of effective regulatory engagement: informed, trust-based, timely, appropriate

  • The three steps to achieve effective regulatory engagement

  • How novel issues like digital technology and real-world evidence influence effective regulatory engagement

  • What to do when things go wrong, e.g., when communication fails or when the FDA decides to take enforcement action

Webinar Details

Engaging with the FDA

Best Practices for Dealing with Warning Letters, Seizures, Injunctions — and More

An FDAnews Webinar

Thursday, December 1, 2022, 11:00 a.m.–12:30 p.m. EST

https://wcg.swoogo.com/engaging-with-the-fda

Price:

$287

Easy Ways to Order:

Online: https://wcg.swoogo.com/engaging-with-the-fda

By phone: 888.838.5578 or 703.538.7600

About WCG FDAnews:

WCG FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on WCG FDAnews’ newsletters, books, databases, webinars and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations. Learn more at fdanews.com.

Share article on social media or email:

[ad_2]

Health

RESTEM Launches NK Cell Therapy Program with Publication of Results from Clinical Study of NK Cell Therapy Targeting Senescence and Age-Associated Disorders

Leave a comment

[ad_1]

“We believe we are the first to report that NK cell therapy, based on our proprietary NK cell therapy platform, can effectively eliminate senescent cells in preclinical and clinical studies,” said Rafael Gonzalez, Chief Development & Science Officer.


Corona, Calif. (PRWEB)

First-in Human NK Cell Therapy Clinical Trial Results Announced:

  • Proof-of-Concept Study Demonstrates Effective Senescent Cell Elimination

  • Transitioning Program to Expanded Human Clinical Trials

  • Internally Developed, GMP-Compliant Manufacturing Platform Scale-Up in Progress

RESTEM Group, Inc., an industry leading cell therapy company focused on the development and commercialization of transformative cell therapies that include the company’s umbilical cord lining stem cells (ULSCs) and natural killer (NK) cell therapies, today announced the results of a human clinical study using the company’s proprietary NK cell therapy to target senescence cells and age-associated disorders. The results were published in the December 2022 issue of the journal Biochemistry and Biophysics Reports, https://www.sciencedirect.com/science/article/pii/S2405580822001807?via%3Dihub. Concurrent with the publication of this study, the company is also transitioning the NK cell therapy program to expanded human clinical trials.

NK Cell Therapy Targeting Senescence and Age-Associated Disorders

RESTEM’s NK cell therapy platform incorporates well validated and proprietary NK cell isolation, activation and expansion methods, leveraging our internally developed manufacturing platform that supports large-scale production, optimized to activate and enhance a patient’s own immune system, harnessing the unique biology of NK cells, with an initial target, age-associated disorders.

Highlighting the results of our published human clinical study, we investigated the use of activated natural killer cells (aNKs) to target and remove senescent cells. Senescent cells have been shown to accumulate in aging tissue and in preclinical studies we demonstrated that aNK cells can effectively eliminate senescent cells. We also report a surprising finding that we believe aNK cells can synergistically work together in a collaborative fashion to target and eliminate senescent cells, suggesting a signal exchange mechanism among aNK cells that enhances senescent cell killing.

To explore further, we performed a human clinical study of five individuals infused with aNK cells looking at senescent biomarkers (p16 & beta-galactosidase) in peripheral blood mononuclear cells (PBMCs) before and after infusion in 2 different cohorts. In cohort 1, we assessed safety, toxicity and inflammatory biomarker profiles at multiple time points. In this cohort, we identified increasing levels of senescent biomarkers that correlated with age, with the youngest individual having the lowest levels and the oldest having the highest. After aNK infusion, at the 14-day time point, all individuals saw a drop in senescent biomarker levels, with the oldest individual with the highest pre-infusion levels seeing the most significant drop. Consistent with the expectation that infused NK cells typically have limited persistence in vivo, typically 30 day or less, at the 90-day time point, we identified an increase in senescent biomarker levels, suggesting that repeat infusions may be necessary to provide a more durable response. To expand our study further, repeated infusions were done on a second cohort of individuals (cohort 2), which were given a second infusion of aNK cells roughly six months apart (day 0 & day 192). In this cohort, we saw a decrease in senescent biomarker levels that was more durable, extending out to 267 days from the second infusion and 459 days from the first infusion, suggesting that repeat administration of aNK cells would also remove senescent cells and produce a therapeutic response that was more durable.

To further extend our understanding of the role that NK cell therapy may play in removing senescence cells in age-associated disorders, we also analyzed inflammatory biomarkers, producing a dynamic range of interactions that may be result from senescent cell elimination, which is unique to each individual, prompting us to explore further in planned clinical studies with larger patient populations.

“The unique biology of natural killer cells represents an attractive and highly-scalable therapeutic platform with significant potential, and we are dedicated to realizing this potential”, said Rafael Gonzalez, PhD, RESTEM’s Chief Development & Science Officer and senior author on the paper. “We believe we are the first to report that activated NK cell therapy, based on our proprietary NK cell therapy platform, can effectively eliminate senescent cells in preclinical and human clinical studies. It’s been a long journey over more than 10 years of development, but in a stepwise fashion, we have systematically addressed multiple technical barriers and now our focus is on bringing what we believe is a true breakthrough in NK cell therapy to a broad patient population suffering from age-associated disorders.”

“In recent years, the cell therapy industry has gained a significant amount of insight into the function of the immune system and how best to translate that insight into effective cell therapies. Based on our established leadership position in cell therapy, RESTEM is focused on bringing that knowledge and experience to patient care,” said David Pyrce, CEO of RESTEM. “Recognizing the importance of bringing our potentially life-changing development efforts to patients, we are now focused on fast-tracking clinical development and manufacturing scale up to bring what we believe will be a real advancement in clinical care to patients around the world suffering from a broad range of age-associated disorders as quickly as possible.”

RESTEM’s NK cell therapy program is based on an optimized, patient-specific NK cell therapy targeting senescence and age-associated disorders. The company plans on entering the clinic in 2023 with this novel NK cell therapy approach. In preparation, the company has established well-differentiated, GMP-compliant production processes to produce clinical product and prepare for pivotal studies and commercialization, enabling the company to advance to an off-the-shelf and ready-to-use therapy available on a worldwide basis.

About RESTEM

RESTEM is a leading clinical-stage biotechnology company focused on the discovery and development of off-the-shelf and ready-to-use, next-generation cell therapies designed to enhance a patient’s own immune system. Our therapies are intended to treat a broad range of disabling diseases and designed to improve patient outcomes, as well as overall health and wellness. Our organization strives to be on the cutting edge of innovative research focused on the development of transformative therapies, with a mission focused on delivering highly effective, safe and accessible cell therapies to patients around the work as rapidly as possible. To realize this mission, we are advancing a pipeline of cell therapies that include our NK cell therapies, as well as our umbilical cord lining stem cell (ULSC) therapy, both synergistically leveraging the company’s unique research, development, and manufacturing expertise. RESTEM is based in Corona, CA.

Contact Information David Pyrce Chief Executive Officer

951-551-0949

dpyrce@restem.com

RESTEM.com

Share article on social media or email:

[ad_2]

Society: Disabled Issues / Disabilities

Governments still have much to do to achieve disability inclusion in climate action

Leave a comment

[ad_1]

Important discussion about a disability inclusive just transition the ILO Pavilion. The panel has 6 speakers, 4 women and 2 men.

COP27 panel discussing the need for a disability inclusive green transition where it was highlighted that progress on disability inclusion must be tracked. Data is key!

“We are excited by the developments at COP27. But we need access to financial resources to develop technical capacity within both the climate and the disability sectors in order to ensure people with disabilities are not left behind,” said Dominic Haslam, IDDC.


GENEVA, Switzerland (PRWEB)

“We suffer climate change the most but are the least included in climate decisions,” said a person with disabilities participating in COP27.

The 27th Conference of Parties to the United Nations Framework Convention on Climate Change (COP27) has concluded in Sharm El-Sheikh, Egypt. Little attention was given to the rights of the one billion people with disabilities who are among the most affected by the climate crisis. Despite years of advocacy by people with disabilities and their allies, and notwithstanding their obligations under the Paris Agreement and the United Nations Convention on the Rights of Persons with Disabilities, governments continue to fail to comply with their duties to respect, protect, and fulfill the rights of persons with disabilities in their response to climate change.

COP27 was ground-breaking for disability inclusion in many ways: the number of persons with disabilities participating multiplied compared to earlier conferences, as did the number of events addressing disability organized by different Governments, UN agencies, and other stakeholders. The main decision as well as the action plan for climate empowerment included references to people with disabilities for the first time.

“Finally, we have actionable language on disability adopted by the COP. The work plan for the Action on Climate Empowerment mandates States to include people with disabilities. If implemented, this means access to climate information, education, and public participation. People with disabilities are being seen in the public forum as the climate actors they have always been,” said Jose Viera, Advocacy Director of the International Disability Alliance (IDA).

“This is indeed great news, achieved after huge effort by the disability movement. But we need to remember that a number of decisions were adopted without the involvement or mention of people with disabilities.”

On the other hand, the U.N. climate negotiations and decision-making processes remain inaccessible for persons with disabilities and their organizations, as they still lack an officially recognized disability caucus or constituency. Challenges to access venues and information for persons with disabilities in COP27 continued, despite UNFCCC’s mandate under the United Nations Disability Inclusion Strategy. The disability community, its requirements, and its perspective have also not been considered in decisions taken by Governments to address climate loss and damage, climate adaptation, or climate finance. The only topic in the negotiations where there has been progress on disability inclusion focused on action for climate empowerment.

The on-going failure of Governments to ensure disability-inclusive climate action is also clear from the latest status report on Disability Inclusion in National Climate Commitments and Policies released by the Disability Inclusive Climate Action Research Program at McGill University and IDA.

Released earlier today and taking into account the most recent versions of the Nationally Determined Contributions (NDCs) submitted by Governments, the report finds that only 37 of the 193 Governments that have signed onto the Paris Agreement refer to persons with disabilities in some way in their NDCs setting out their main commitments on climate action.

Of these, only 14 State Governments include concrete measures to ensure disability inclusion in climate policies. At the domestic level, only 46 Governments refer to persons with disabilities in their climate adaptation policies, and only 15 Governments include concrete measures to ensure that persons with disabilities are included in efforts to ensure that populations can cope with the impact of a changing climate.

The report concludes that even when Governments refer to disability, many do so in a cursory manner, without including meaningful mechanisms to consult people with disabilities or ensure their rights are respected in climate policies.

The status report shows that there is one bright spot. The second NDC submitted by Vanuatu stands alone in setting out a number of concrete steps to involve people with disabilities and integrate their needs in its responses to climate change.

“The failure to integrate the disability community and their rights in climate policies does not only put the lives of people with disabilities at risk and reinforce social inequalities. It undermines the effectiveness of our efforts to reduce carbon emissions and ensure the climate resilience of our societies,” explains Sébastien Jodoin, law professor and director of the Disability Inclusive Climate Action Research Program at McGill University, who co-authored the status report.

“The example of Vanuatu demonstrates that adopting disability-inclusive climate policies is not out of reach, but quite feasible with genuine commitment and meaningful consultation with persons with disabilities and their representative organizations.”

“We are excited by the developments at COP27. But we need access to financial resources to develop technical capacity within both the climate and the disability sectors in order to ensure people with disabilities are not left behind,” said Dominic Haslam, on behalf of the International Disability and Development Consortium. “We call on governments, mainstream environmental organizations and climate advocates to prioritize disability inclusion in their work, and help us deliver on this shared vision.”

The report is available in PDF here and in Word here.

For additional information, contact:

Elham Youssefian

Inclusive Humanitarian Action and Disaster Risk Reduction Advisor, IDA

Email: eyoussefian@ida-secretariat.org

For additional information on the report, its methodology and findings, contact:

Sébastien Jodoin

Associate Professor & Canada Research Chair in Human Rights, Health, and the Environment, McGill University, Faculty of Law

Email: sebastien.jodoin-pilon@mcgill.ca

For additional information on IDDC, contact:

Dominic Haslam, IDDC Chair

Email: dhaslam@sightsavers.org

Share article on social media or email:

[ad_2]

Health

Vegan Life Nutrition Introduces Vegan Prenatal and Postnatal Vitamins

Leave a comment

[ad_1]

News Image

“We took the next step to find out what we would have to do to enhance that experience for the mom and baby in prenatal and postnatal situations.,” said Jim Rex, President of The GHT Companies. “We are proud to assist not only vegan women, but all women, on their pregnancy and motherhood journeys.”


SAN DIEGO, Calif. (PRWEB)

Vegan Life Nutrition, a division of The GHT Companies, a family of supplement manufacturers, has launched a new line of vegan prenatal and postnatal vitamins that support the mother and baby before, during, and after pregnancy.

The Prenatal Focus Bundle and Postnatal Focus Bundle each include a bottle of Prenatal & Postnatal Basic, a daily supplement that provides 24 essential plant-sourced vitamins and minerals for healthy prenatal and postnatal care.

These vitamins and minerals include: Vitamin A (beta carotene), Vitamin C (ascorbic acid), Vitamin D (cholecalciferol), Vitamin E (d-alpha-tocopherol), Vitamin K (menaquinone K2-MK7), Thiamin (thiamin mononitrate), Riboflavin (riboflavin sodium phosphate), Niacin (niacinamide), Vitamin B6 (pyridoxal-5-phosphate), Folate ((6s)-5-methyltetrahydrofolic acid, glucosamine salt), Vitamin B12 (methylcobalamin), Biotin (d-biotin), Pantothenic Acid (d-calcium pantothenate), Calcium (calcium carbonate, plant-derived), Iron (ferrous bisglycinate chelate), Iodine (kelp, laminaria digitata), Magnesium (magnesium chelate), Zinc (zinc bisglycinate chelate), Selenium (selenium glycinate), Copper (copper bisglycinate chelate), Manganese (manganese bisglycinatechelate), Chromium (chromium nicotinate glycinate chelate), and Molybdenum (molybdenum glycinate chelate)

In the Prenatal Bundle, customers also receive a bottle of Vegan Life’s Prenatal Focus that contains 550mg of Choline, a critical ingredient supporting brain and neural tube development. In the Postnatal Bundle, customers receive a bottle of Postnatal Focus, which provides extra servings of Vitamin D, Thiamine, Riboflavin, Niacin, and Folate, plus 475mgs of Choline.

“When we realized that moms were having a difficult time determining which prenatal and postnatal supplements to use, we knew that we had to develop a regimen that would prove to be the best of the best,” said Jim Rex, President of The GHT Companies. “Vegan Life Nutrition is dedicated to providing everyone – especially those who follow a vegan or plant-based lifestyle – with the essential vitamins and minerals that we all need daily, and we are proud to assist not only vegan women, but all women, on their pregnancy and motherhood journeys.”

The Prenatal Focus and Postnatal Focus bundles were created to help mothers maintain healthy digestion, promote healthy cell division and development, support the fetal brain, spinal cord, heart, muscle, bone, nerve, and skin development, support placenta growth, and promote red blood cell development.*

“We took the next step to find out what we would have to do to enhance that experience for the mom and baby in prenatal and postnatal situations. In Prenatal Focus, the only ingredient we added was Choline, which is critical as it has been identified to assist the fetus in neural tube development. So without a doubt, we added that as a prenatal ingredient,” said Rex. “As for Postnatal Focus, we added seven or eight vitamins, including Choline, that assist in replenishing nutrients that may have been depleted during birth to help the mom recuperate and be a strong, sustainable, support for her baby during the nursing phase.”

The Prenatal Focus Bundle and the Postnatal Focus Bundle cost $39.95 each. To order, you can visit Vegan Life Nutrition’s website or shop Prenatal and Postnatal on Amazon.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Information and statements made are for educational purposes and are not intended to replace the advice of your health care professional.

==================================================================

About Vegan Life Nutrition

At Vegan Life Nutrition, we offer a complete line of nutritional products for vegans and non-vegans alike, using nothing but the cleanest, highest quality plant-based ingredients to support your healthy lifestyle. We harness the power of vegan components in our products, building our formulations around powerful ingredients from natural plant sources. Our clean nutraceuticals are the best way to receive the nutritional support you need.

Through our exclusive partnerships with industry leaders across the globe, we have constant access to scientific breakthroughs that push the boundaries of plant-based nutrition. Backed by the groundbreaking knowledge that these partnerships bring, our in-house scientists and manufacturing team work tirelessly to perfect and expand our premier plant technologies and naturally-derived supplement blends. With processes that are held to the highest standards, we bridge the gap between the most cutting-edge nutritional science and your personal good health.

About The GHT Companies

The GHT Companies is one of the most trusted names in the nutritional supplement field since 1996. The group is structured to collaborate with founding scientists to develop their unique ingredient/product discoveries and to deliver industry-leading, high-quality consumer products, and ingredients on a global basis.

The GHT Companies uses its unique business structure of 5 diverse subsidiaries that touch on all facets of the nutraceutical industry in order to provide products and services to customers in the most effective way possible.

Share article on social media or email:

[ad_2]

Health

Apollo Demonstrates New Enterprise Imaging Workflows at 2022 RSNA Annual Meeting

Leave a comment

[ad_1]

arcc supports health systems to organize and access medical imaging across numerous departments, provides efficient clinical workflows that drive effective care, and converges viewing into a single pane of glass.


TYSONS, Va. (PRWEB)

Apollo, a leading provider of enterprise imaging and clinical multimedia management solutions, announces new capabilities in the latest version of its enterprise imaging solution, arcc®. arcc supports health systems to organize and access medical imaging across numerous departments, provides efficient clinical workflows that drive effective care, and converges viewing into a single pane of glass. This latest version provides an upgrade to the existing comparison view functionality to provide a fully functional accession/image comparison view mode in the arccClinical module.

Apollo is exhibiting in Booth 6603 in the North Hall at the Radiological Society for North America (RSNA) annual meeting in Chicago, November 27-30, 2022. Our Enterprise Imaging experts will be available in our booth to demonstrate these new capabilities and discuss ways health systems can use arcc to streamline clinical workflows to drive effective care.

The Apollo Repository for Clinical Content, arcc v10.7, now features an enhanced side by side comparison view workflow mode. Enabling clinicians to quickly and easily compare patient clinical images from two accessions/orders, each with an independent image timeline. In addition, users are able to customize the image metadata displayed with the clinical images in the patient image timeline.

arcc v10.7 is comprised of several modules. arccClinical is the clinical application and universal viewer supports viewing images from various modalities side by side on a single pane of glass. It interfaces with the EMR providing the ability to view DICOM studies and non-DICOM clinical images directly from the EMR. arccClinical provides both orders- and encounters-based workflows for 45 specialty departments across the healthcare enterprise. This enables every department throughout the enterprise to securely acquire, manage, and access all clinical content through one platform.

arccCore is an enterprise clinical content repository and IT management platform that incorporates VNA functionality, enterprise imaging management tools, advanced security and reporting, storage management, and much more. It provides the ability to interface with modality devices across the enterprise and ensure the accurate assignment of relevant metadata.

arccMobile is the companion mobile application enabling everyone on the healthcare team to securely capture pictures or video recordings and immediately upload and incorporate these multimedia objects in patient care.

About Apollo

Apollo is a healthcare IT company with a reputation for delivering quality Enterprise Imaging solutions that address both clinical multimedia workflow management needs and vendor neutral storage requirements. Apollo’s Enterprise Imaging solution, arcc, provides a holistic longitudinal view of all patient data and focuses on clinical workflows, interoperability, and connectivity so that every department throughout the entire enterprise can securely acquire, view, manage, store, and access all clinical content. Integrating arcc to the electronic health record (EHR) provides clinicians a single view of the longitudinal patient record to achieve the goal of: ONE Patient, ONE click, EVERY ‘ology. Used successfully in hospitals across the United States and Canada for 28 years, visit https://www.apolloei.com/ to learn more.

Share article on social media or email:

[ad_2]

Health

3 Ways to Respond to Shifts in Healthcare Realities in 2023 and Beyond, Upcoming Webinar Hosted by Xtalks

Leave a comment

[ad_1]

The featured speakers will discuss and apply interactive activities to each, with the goal of leaving attendees more confident in their ability to build their next — the future.


TORONTO (PRWEB)

It’s not easy to plan for a future that cannot be predicted. But trends can be tracked and applied to challenges to help realize the future, faster. Part presentation, part workshop, this webinar will focus on three key trends sure to shift healthcare in the year ahead. The featured speakers will discuss and apply interactive activities to each, with the goal of leaving attendees more confident in their ability to build their next — the future.

Register to learn more about ways to respond to shifts in healthcare realities in 2023 and beyond.

Join Leigh Householder, EVP / Managing Director, Technology and Data Science, Syneos Health; and Alastair Macdonald, SVP, Global Client Solutions, Syneos Health, for the live webinar on Monday, December 5, 2022 at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit Building Next: 3 Ways to Respond to Shifts in Healthcare Realities in 2023 and Beyond.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

[ad_2]

Health

Nitrosamine Impurities in Rifampin – What Does it Mean for Your Drug-Drug Interaction (DDI) Study? Upcoming Webinar Hosted by Xtalks

Leave a comment

[ad_1]

The speakers propose overcoming rifampin impurity challenges with the use of phenytoin for healthy volunteer pharmacokinetic drug-drug interaction studies.


TORONTO (PRWEB)

N-Nitrosamine impurity findings in marketed formulations of rifampin have disrupted drug development. As a strong cytochrome P450 3A4 (CYP3A4) inducer, rifampin was regularly co-administered with investigational products during pharmacokinetic drug-drug interaction studies. However, due to recent impurity issues, its application in these studies has been suspended in both the US and EU. This webinar will examine the root cause of rifampin impurity and describe the industry and regulatory response to this issue. In addition, the featured speakers will address alternative approaches and CYP3A inducers to encourage the continuation of drug-drug interaction studies and drug development.

N-Nitrosamines are a class of chemicals recognized as a “cohort of concern” due to their mutagenic and carcinogenic potential. Typically, levels above an acceptable intake limit may lead to a probable or possible risk of cancer in humans. Rifampin capsules were found to contain 1-methyl-4-nitrosopiperazine (MNP) above the acceptable intake limit of 0.16 ppm. However, it’s important to note that nitrosamines are not limited to drug products, and low levels can be found in drinking water, processed meats and tobacco exposure. Therefore, in theory, a diet low in nitrosamines could offset any potential exposure during rifampin drug-drug interaction studies.

Alternatively, other CYP3A inducers could be applied in these studies. While the US Food and Drug Administration (FDA) does provide a list of several candidates, in practice, many of these substitutes are not ideal for healthy volunteer studies due to black-box warnings (eg. carbamazepine), risk of serious adverse events (eg. apalutamide, enzalutamide, mitotane), or variation in response (St John’s wort).

The speakers propose overcoming rifampin impurity challenges with the use of phenytoin for healthy volunteer pharmacokinetic drug-drug interaction studies.

Register to learn about optimizing study design, anticipated effect size and common adverse events healthy volunteers may experience with phenytoin administration during drug-drug interaction studies.

Join experts from Celerion, Aernout van Haarst, PhD, Director of Scientific Affairs; and Sabina Paglialunga, PhD, Director of Scientific Affairs, for the live webinar on Wednesday, December 7, 2022, at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit Nitrosamine Impurities in Rifampin – What Does it Mean for Your Drug-Drug Interaction (DDI) Study?

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

[ad_2]